Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (3) , 593-596
- https://doi.org/10.1016/s0090-8258(03)00399-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The role of gemcitabine-based doublets in the management of ovarian carcinoma.Seminars in Oncology, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsJournal of Clinical Oncology, 2000
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II TrialGynecologic Oncology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994